Home / Pharmaceuticals / Biosimilars Treatment Market By Product (Recombinant Non – Glycosylated Proteins, Recombinant Glycosylated Proteins, Recombinant Peptides), By Application (Oncology, Chronic And Autoimmune Disease, Blood Disorders, Growth Hormone Disease, Infectious Disease) - Growth, Future Prospects And Competitive Analysis 2017 - 2025

Biosimilars Treatment Market By Product (Recombinant Non – Glycosylated Proteins, Recombinant Glycosylated Proteins, Recombinant Peptides), By Application (Oncology, Chronic And Autoimmune Disease, Blood Disorders, Growth Hormone Disease, Infectious Disease) - Growth, Future Prospects And Competitive Analysis 2017 - 2025

Published: Apr 2017 | Report Code: 58422-04-17

This report on global biosimilars market studies the increasing demand for biosimilars as the number of biologics drugs used for chronic diseases are set to expire in the next 3-5 years, growing pressure to curtail healthcare expenditure, cost effectiveness of biosimilars and strategic collaborations resulting into enhanced productivity and clinical trials activities for biosimilars.

For the purpose of this study, the biosimilars market is segmented into product (recombinant non-glycosylated proteins, recombinant glycosylated proteins and recombinant peptides) and application type (oncology, chronic and autoimmune disorders, blood disorders, growth hormone disease and infectious disease); Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.

The pipeline analysis for biosimilars market comprises projected market sales of Phase III drugs estimated till 2025. We have estimated sales of very specific molecules based on the type (SB4, HX575, ABP 980, and M834), sponsor, depicted peak sales by leading market experts and other factors.

The geographic segmentation of the global biosimilars market is performed for the regions North America, Europe, Asia Pacific, Latin America and Middle East and Africa markets. The regions are also further sub-segmented on the basis of major countries. Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.

Biosimilars Market

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Biosimilars Market Portraiture
2.2 Global Biosimilars Market, by Product, 2016 (US$ Mn)
2.3 Global Biosimilars Market, by Application 2016 (US$ Mn)
2.4 Global Biosimilars Market, by Geography, 2016 (Value %)

Chapter 3 Global Biosimilars Market Overview
3.1 Overview
3.2 Market Drivers
3.2.1 Rising prevalence of cancer and chronic disease and geriatric population
3.2.2 Patent expiry of biologics and government initiatives to promote biosimilars
3.3 Market Restraints
3.3.1 High complexities involved in the manufacturing of biosimilars
3.3.2 Rigorous regulatory frame work governing their approval in countries around the world
3.4 Market Opportunities
3.4.1 Cost effectiveness of biosimilars in comparison to costly biological drugs.
3.5 Attractive Investment Proposition
3.6 Market Competition Assessment: Biosimilars , by Key Players

Chapter 4 Global Biosimilar Market, By Type of Product
4.1 Introduction
4.2 Recombinant non – glycosylated proteins
4.3 Recombinant glycosylated proteins
4.4 Recombinant peptides

Chapter 5 Global Biosimilar Market, By Application
5.1 Market Analysis
5.2 Oncology
5.3 Chronic and autoimmune disease
5.4 Blood disorders
5.5 Growth hormone disease
5.6 Infectious disease

Chapter 6 Global Biosimilar Market, By Geography
6.1 Preface
6.2 North America
6.3 Europe
6.4 Asia Pacific
6.5 Latin America
6.6 Middle East and Africa

Chapter 7 Company Profiles
7.1 Pfizer, Inc.
7.2 Sandoz International GmbH
7.3 Teva Pharmaceutical Industries Limited
7.4 Amgen Inc.
7.5 Biocon
7.6 Dr. Reddy’s Laboratories
7.7 F. Hoffman – La Roche Ltd.
7.8 Celltrion, Inc.
7.9 Samsung Bioepis
7.10 Eli Lily, Inc.

List Of Tables :

TABLE 1 Global Biosimilars Market, By Product, 2015-2025 (US$ Mn)
TABLE 2 Global Biosimilars Market, By Application, 2015-2025 (US$ Mn)
TABLE 3 Global Biosimilars Market, By Geography, 2015 – 2025 (US$ Mn)
TABLE 4 Pfizer, Inc. : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 5 Sandoz International GmbH : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 6 Teva pharmaceutical Industries Ltd. : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 7 Amgen Inc. : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 8 Biocon: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 9 Dr. Reddy’s Laboratories : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 10 F. Hoffman – La Roche Ltd. : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 11 Celltrion, Inc. : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 12 Samsung Bioepis : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)
TABLE 13 Eli Lily, Inc. : Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Key Industries Served, SCOT Analysis, Recent Developments)

List Of Figures :

FIG. 1 Biosimilars Market: Research Methodology
FIG. 2 Global Biosimilars Market, by Product 2016 (US$ Mn)
FIG. 3 Global Biosimilars Market, by Application, 2016 (US$ Mn)
FIG. 4 Global Biosimilars Market, by Geography, 2016 (Value %)
FIG. 5 Attractive Investment Proposition, by Geography,2016
FIG. 6 Market Positioning of Key Biosimilars Vendors, 2016
FIG. 7 Recombinant non – glycosylated proteins Product Market, 2015 – 2025 (US$ Mn)
FIG. 8 Recombinant glycosylated proteins Product Market, 2015 – 2025 (US$ Mn)
FIG. 9 Recombinant peptides Product Market, 2015 – 2025 (US$ Mn)
FIG. 10 Oncology Application Market, 2015 – 2025 (US$ Mn)
FIG. 11 Chronic and autoimmune disease Appication Market, 2015 – 2025 (US$ Mn)
FIG. 12 Blood disorders Application Market, 2015 – 2025 (US$ Mn)
FIG. 13 Growth hormone disease Application Market, 2015 – 2025 (US$ Mn)
FIG. 14 Infectious disease Application Market, 2015 – 2025 (US$ Mn)
FIG. 15 North America Biosimilars Market , 2015 – 2025 (US$ Mn)
FIG. 16 Europe Biosimilars Market , 2015 – 2025 (US$ Mn)
FIG. 17 Asia-Pacific Biosimilars Market , 2015 – 2025 (US$ Mn)
FIG. 18 Latin America Biosimilars Market , 2015 – 2025 (US$ Mn)
FIG. 19 Middle East and Africa Biosimilars Market , 2015 – 2025 (US$ Mn)

Based on products types, the global biosimilars market is categorized into:

  • Recombinant non-glycosylated proteins (Insulin, Filgrastim, Somatropin)
  • Recombinant glycosylated proteins (Monoclonal antibodies, Erythropoietin)
  • Recombinant peptides (Glucagon, Calcitonin)

Biosimilars Treatment Market

According to market experts, the recombinant non-glycosylated proteins is expected to dominate the product segment due to growing incidence of diabetes, presence of several versions of insulin in the market and launch of cost effective products. The recombinant glycosylated proteins will record the fastest growth in the biosimilars product segment as need of erythropoietin to counter blood related disorders is increasing due to high priced biologics and frequent application. Overall, the global biosimilars market is highly competitive with presence of multiple players like Pfizer, Inc., Biocon, F.Hoffman-La Roche AG, Amgen, Inc. etc. specializing in respective fields. Consolidation activities are being increasingly witnessed on the competitive front with a view to increase the technological advancement in the biosimilars market.

Based on Application, the global biosimilars market is categorized into:

  • Oncology
  • Chronic and autoimmune disease
  • Blood disorder
  • Growth hormone
  • Infectious disease

Biosimilars Treatment Market

Oncology is expected to dominate the application segment due to rising incidences of cancer, high cost of biologics, and the pressure to reduce the healthcare expenditure. In base year 2016, biosimilars application for autoimmune disease and chronic disease showed great potential due to the changing off patent scenario. During the forecast period 2017 – 2025 blood disease biosimilars are expected to project a significant growth due to high priced reference biologics and their frequent application. The key factors assisting the biosimilar market growth are the increasing prevalence of chronic disease, aging population, and cost effectiveness of biosimilars and government initiatives to promote biosimilars for e.g. Europe Medicines Agency (EMA) has finalized the guidelines on biosimilars with its elements described in ICH (Q5E).

For the purpose of this study, the global biosimilars market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Biosimilars Treatment Market

North America was observed as the largest market for biosimilars in the base year 2016. According to Centre for Disease Control and Prevention, in 2012 about half the adult’s i.e.  117 million people suffered from chronic disease, which can be considered as a potential market for biosimilars. According to World Health Organization, over one third of the European population above the age of 15 suffer from chronic disease. Europe is expected to be the second largest market due to rising public awareness of chronic disease, improved healthcare infrastructure. Newly approved biosimilars molecules have a good acceptance and penetration rate in the European market. Growth of Asia Pacific for biosimilars market is attributed by factors like rising prevalence of chronic disease, increasing investments in R&D and higher disposable income in these regions. However, factors such as high prevalence of chronic disease, developing healthcare infrastructure, increasing awareness among people about health care and aging population are going to fuel the rapid growth of biosimilars market in Latin America and Middle East and Africa region in the near future.   

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients